Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 405-406

  Fuji, S ^a   Kim, S W ^a   Mori, S ^a   Furuta, K ^a   Tanosaki, R ^a   Heike, Y ^a   Takaue, Y ^a   Fukuda, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; LETTER; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; GRAFT VS HOST DISEASE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 76749102352     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.154     Document Type: Letter

References (7)

1. Hammer MJ, Casper C, Gooley TA, O'Donnell PV, Boeckh M, Hirsch IB. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009; 15: 344-351.
2. Fuji S, Kim SW, Mori S, Kamiya S, Yoshimura K, Yokoyama H et al. Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study. Bone Marrow Transplant 19 January 2009 [e-pub ahead of print].
3. Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation 2007; 84: 814-820.
4. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007; 36: 873-890.
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
6. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
7. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.